Recent Finacing
Recent Raise
EnGeneIC develops an antibody‑targeted EDV nanocell platform delivering chemotherapeutics, targeted drugs, and RNAi into tumor cells, operating from New York and Sydney and running Phase 1/2a oncology trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors